Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Extends Pediatric Psoriasis Study: What ...

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis ...

Zasocitinib is also being evaluated in a head-to-head study against Bristol Myers Squibb’s Sotyktu (deucravacitinib) in ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily pill helped patients achieve clear or almost clear skin. The ...

Patients with moderate-to-severe plaque psoriasis who took the once-daily pill showed significantly clearer skin compared with those on placebo or the existing therapy apremilast, the company said.

Takeda Pharmaceutical Co. rose the most in seven months on Friday after the drugmaker said its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...